ReShape Lifesciences Closes $2.6M Stock Offering

ReShape Lifesciences ( (RSLS) ) has provided an announcement.

On June 8, 2025, ReShape Lifesciences entered into a Placement Agency Agreement with Maxim Group LLC to issue and sell 1,054,604 shares of common stock at $2.50 per share, closing the offering on June 9, 2025. The company raised approximately $2.6 million in gross proceeds, which it plans to use for general corporate purposes, including its proposed merger with Vyome Therapeutics and asset sale to Ninjour Health International. Maxim Group LLC acted as the exclusive placement agent, receiving a fee and warrants as compensation.

Spark’s Take on RSLS Stock

According to Spark, TipRanks’ AI Analyst, RSLS is a Underperform.

ReShape Lifesciences is facing significant financial challenges, with persistent losses, negative equity, and cash flow issues. The technical indicators show a bearish trend with potential oversold conditions. Valuation is poor due to a negative P/E ratio. Despite some positive developments highlighted in the earnings call, such as revenue growth and cost reductions, the overall outlook remains concerning due to financial instability and competitive pressures. The recent board resignation further complicates the situation by potentially affecting compliance and investor confidence.

To see Spark’s full report on RSLS stock, click here.

More about ReShape Lifesciences

ReShape Lifesciences is a leading American company in the weight loss and metabolic health industry, offering a range of FDA-approved products and services. These include the Lap-Band systems for obesity treatment, the ReShape Diabetes Neuromodulation system for plasma glucose regulation, and the Obalon balloon technology for non-surgical weight loss.

Average Trading Volume: 1,690,004

Technical Sentiment Signal: Sell

Current Market Cap: $1.82M

For an in-depth examination of RSLS stock, go to TipRanks’ Overview page.